Shots:

• Ascentage will be responsible to sponsor the P-Ib/II trial (NCT03611868) which involves assessing of APG-115 in combination with Keytruda- to evaluate its safety and efficacy in solid tumors (i-e.- NSCLC- melanoma- Urothelial cancer- Liposarcoma- MPNST and ATM mutated/p53 WT tumors resistant or relapsed to PD-1/PD-L1 treatment or without previous PD-1/PD-L1 treatment)
• The companies will exchange information about the study with the access of the joint development committee. The P-II trial is being initiated and expected to enroll 80 patients in multiple sites across the US
•  APG-115 is a small-molecule inhibitor of the MDM2-p53 PPI administered orally and has been commenced in three trials in the US and is also the first MDM2-p53 inhibitor to enter in clinical studies in China. Additionally- the P-Ib trial data is being published in ASCO 2020 showing well-tolerated and with anti-tumor effects in several tumor types

Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter